Immunotherapy before surgery helps shrink tumors in patients with desmoplastic melanoma
New results from a clinical trial co-led by UCLA investigators demonstrate how treating desmoplastic melanoma, a rare and aggressive skin cancer, with immunotherapy before surgery can dramatically shrink or even eliminate tumors, sparing patients from more aggressive surgeries and preserving their quality of life.
The findings, published in Nature Cancer, show that 71% of patients who received the immunotherapy drug pembrolizumab, an anti-PD-1 immune checkpoint inhibitor that stimulates the body’s immune system to fight ...